An interventional study of DragonFly M2 Transcatheter Mitral Valve Repair System in Mitral Valve (MV) Regurgitation, sponsored by Hangzhou Valgen Medtech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Hangzhou Valgen Medtech Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Gastroesophageal Reflux with a site in China — 16 open to participants now, 17 under way, none of them phase 3. Gastroesophageal Reflux · China.
Among the 56 studies in Gastroesophageal Reflux with a site in China, this one is the 29th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, reaches primary completion later than 6 of the 16 other live ones, and was the 47th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →16 of the 56 studies in Gastroesophageal Reflux with a site in China are open now. Recruiting first, the newest first:
Xinghua Liu · Sites in China
Ages 18–65
Beijing Friendship Hospital · Sites in China
Ages 18–90
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Shanghai Hutchison Pharmaceuticals Limited · Sites in China
Ages 18–75
Nanchong Central Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7 · Phase 4 2
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 53 is below the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 90 across the 39 interventional studies, 1,625 across the 17 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 56 have an industry lead sponsor. The 10 most frequent:
Hangzhou Valgen Medtech Co., Ltd is the lead sponsor of 12 studies on the registry; 7 are open to participants now.
Hangzhou Valgen Medtech Co., Ltd has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
5 of the studies in Gastroesophageal Reflux with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07749989Beijing Friendship HospitalA Retrospective Analysis of Patients With Gastroesophageal Reflux Disease Based on a Prospective Clinical Dataset | 2027-04 |
| NCT07943611Nanchong Central HospitalLaparoscopic Fundoplication With or Without Fixation to the Diaphragm for Gastroesophageal Reflux Disease or Hiatal Hernia | 2027-06-30 |
| NCT06755671Shanghai Hutchison Pharmaceuticals LimitedA Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms | 2027-06-30 |
| NCT07795645Beijing Friendship HospitalValidating a Medical AI Fine-Tuning Platform for Major Diseases | 2027-08-31 |
| NCT07854613China-Japan Friendship HospitalDe Novo Gastroesophageal Reflux Disease After Sleeve Gastrectomy With and Without Omentopexy | 2027-10-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Gastroesophageal Reflux with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To confirm the effectiveness and safety of the DragonFly M2 Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk subjects.The safety and effectiveness of the first-generation device(Dragonfly Transcatheter Mitral Valve Repair System)have been previously demonstrated. This study aims to further confirm the safety and effectiveness of the new device following structural optimization based on the first-generation design.
This is a prospective, multicentric clinical investigation.
Subjects to be included in this clinical investigation suffer from symptomatic chronic moderate-to-severe (3+) or severe (4+) DMR with high or prohibitive surgical risk judged by a local investigation site's heart team .
After signing an informed consent form, subjects in the experimental group will undergo the transcatheter mitral valve repair procedure using the DragonFly M2 Transcatheter Mitral Valve Clip System. All subjects were followed up immediately after procedure, before discharge, 30 days , 6 months, 12 months after procedure, and 2, 3, 4, and 5 years after procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1.≥ 18 years old. 2.Moderate to severe (3+) or severe (4+) chronic DMR determined by transthoracic echocardiography.
Exclusion Criteria:
1)Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 2) The presence of other severe heart valve disease requiring surgical intervention.
3) Prior mitral valve leaflet surgery or transcatheter mitral valve intervention.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter mitral valve repair with the DragonFly M2 System in patients with degenerative mitral regurgitation
Device: DragonFly M2 Transcatheter Mitral Valve Repair System
Edge-to-edge repair with DragonFly M2 System
Procedure success
Procedure success: device implanted successfully, MR ≤ 2+ at discharge (or 30-day echo if unavailable), and no death or device-related reintervention within 30 days post-procedure.
Time frame: 30 Days
Single-click release success
successful clip detachment from the delivery system at the intended position during the first release attempt
Time frame: Intraoperative
Acute device success
One or more Dragonfly devices are successfully delivered and released, edge-to-edge leaflet repair confirmed by echocardiogram, and successfully withdrawal of the delivery catheter.
Time frame: Immediately after procedure
surgical intervention
surgical interventions due to post-procedural mitral valve dysfunction
Time frame: 30 days, 6 months, and 12 months
NYHA Class
Number of patients with New York Heart Association (NYHA) Function Class I or II.
Time frame: 30 days, 6 months, and 12 months
Quality of life improvement
Improvement in quality of life (QoL) over baseline, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Time frame: 30 days, 6 months, and 12 months
Incidence of major adverse events (MAEs)
MAE is defined as a combined clinical endpoint of death, stroke, myocardial infarction, renal failure, and nonelective cardiovascular surgery for device or procedure-related adverse events occurring after transseptal catheterization.
Time frame: 30 days, 6 months, and 12 months
All-cause mortality
Percentage of all-cause death includes cardiac death, non-cardiac death, and death from unknown causes.
Time frame: 30 days, 6 months, and 12 months
Cardiovascular death
Cardiovascular death
Time frame: 30 Days, 6 months, 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Jul 2026, 6 months later.
Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 6 months is below that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hangzhou Valgen Medtech Co., Ltd